XML 39 R28.htm IDEA: XBRL DOCUMENT v3.10.0.1
Collaborative Arrangements (Tables)
 9 Months Ended
Sep. 30, 2018
Collaborative Arrangements [Abstract]  
Collaboration Arrangements
Summarized information related to this collaboration is as follows:
 
Three Months Ended 
 September 30,
 
Nine Months Ended 
 September 30,
($ in millions)
2018
 
2017
 
2018
 
2017
Alliance revenues
$
49

 
$
5

 
$
125

 
$
5

 
 
 
 
 
 
 
 
Materials and production (1)
12

 
—

 
48

 
—

Marketing and administrative
12

 
—

 
28

 
—

Research and development (2)
47

 
2,377

 
118

 
2,377

 
 
 
 
 
 
 
 
($ in millions)
 
 
 
 
September 30, 2018
 
December 31, 2017
Receivables from AstraZeneca
 
 
 
 
$
46

 
$
12

Payables to AstraZeneca (3)
 
 
 
 
892

 
643

(1) Represents amortization of capitalized milestone payments.
(2) Amounts for the third quarter and first nine months of 2017 include $2.35 billion related to the upfront payment and future license option payments.
(3) Includes accrued milestone and license option payments.
Summarized information related to this collaboration is as follows:
 
Three Months Ended 
 September 30,
 
Nine Months Ended 
 September 30,
($ in millions)
2018
 
2017
 
2018
 
2017
Net product sales recorded by Merck
$
47

 
$
38

 
$
138

 
$
105

Merck’s profit share from sales in Bayer’s marketing territories
47

 
32

 
100

 
116

Total sales
94

 
70

 
238

 
221

 
 
 
 
 
 
 
 
Materials and production (1)
29

 
25

 
188

 
73

Marketing and administrative
11

 
6

 
26

 
18

Research and development
34

 
27

 
90

 
78

 
 
 
 
 
 
 
 
($ in millions)
 
 
 
 
September 30, 2018
 
December 31, 2017
Receivables from Bayer
 
 


 
$
36

 
$
33

Payables to Bayer (2)
 
 


 
375

 
352

(1) Includes amortization of intangible assets.
(2) Includes accrued milestone payments.
Summarized information related to this collaboration is as follows:
($ in millions)
Three Months Ended 
 September 30, 2018
 
Nine Months Ended September 30, 2018
Alliance revenues
$
43

 
$
78

 
 
 
 
Materials and production (1)
8

 
9

Marketing and administrative
5

 
7

Research and development (2)
36

 
1,473

 
 
 
 
($ in millions)
 
 
September 30, 2018
Receivables from Eisai
 
 
$
42

Payables to Eisai (3)
 
 
733

(1) Represents amortization of capitalized milestone payments.
(2) Amount for the first nine months of 2018 includes $1.4 billion related to the upfront payment and future license option payments.
(3) Includes accrued milestone and license option payments.